|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.96/-7.41
|
企業價值
318.53M
|
資產負債 |
每股賬面淨值
18.18
|
現金流量 |
現金流量率
--
|
損益表 |
收益
12.60M
|
每股收益
1.82
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/10/31 19:53 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates. |